Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.51 |
| ▸ | NOS1 | P29475 | 4/20 | 0.51 |
| ▸ | NOS3 | P29474 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | OTC | P00480 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ARG1 | P05089 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180969 | 1.00 | KDM4E (0.56) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL919222 | 1.00 | KDM4E (0.56) | KDM4EMAPK1HIF1AGSRPAOX | |
| Hydrochloric Acid SCHEMBL28854969 | 0.98 | KDM4E (0.54) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL30125060 | 0.98 | KDM4E (0.59) | KDM4EMAPK1HIF1AGSRPAOX | |
| Hydrochloric Acid SCHEMBL15669798 | 0.98 | KDM4E (0.54) | KDM4EMAPK1HIF1AGSRPAOX | |
| Ethylene SCHEMBL28796155 | 0.96 | KDM4E (0.52) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL976174 | 0.94 | OTC (0.57) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL3503365 | 0.94 | OTC (0.57) | KDM4EMAPK1HIF1AGSRPAOX | |
| SCHEMBL2238055 | 0.94 | OTC (0.57) | KDM4EMAPK1HIF1AGSRPAOX | |
| Lysine SCHEMBL18825683 | 0.93 | GSR (0.67) | KDM4EMAPK1HIF1AGSRPAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1697 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122084906-A | Plasma metabolism marker for early diagnosis or prediction of gestational diabetes mellitus and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026099467-A1 | COMPOSITION FOR USE IN PROMOTING BRAIN DEVELOPMENT AND FUNCTIONING | Société des Produits Nestlé S.A. (CH) | 2026-05-15 | — | — | WO | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | UNIVERSITAET WIEN (AT) | 2026-04-30 | — | — | US | claimed |
| EP-4729529-A1 | PREPARATION OF PEPTIDE INHIBITOR OF INTERLEUKIN-23 RECEPTOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4720086-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | claimed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-3570864-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| WO-2005040097-A1 | RESOLUTION OF 3-AMINO ALKYLNITRILES | PFIZER PRODUCTS INC. (US) | 2005-05-06 | — | — | WO | claimed |
| EP-1344515-A1 | SKIN COSMETICS | Shu Uemura Cosmetics Inc. (JP) | 2003-09-17 | — | — | EP | claimed |
| EP-0749429-B1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AG (DE) | 1999-06-30 | — | — | EP | claimed |
| EP-0618809-A1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | claimed |
| EP-0618809-A4 | BRADYKININ TYPE PEPTIDES. | SCIOS NOVA INC (US) | 1994-07-28 | — | — | EP | claimed |
| WO-1994008607-A1 | NOVEL PSEUDOPEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS NOVA INC. (US) | 1994-04-28 | — | — | WO | claimed |
| US-5284872-A | Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof | SCHWARZ PHARMA AG (DE) | 1994-02-08 | — | — | US | claimed |
| WO-1993011789-A1 | MODIFIED POSITION (7) BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1993-06-24 | — | — | WO | claimed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992018155-A1 | BRADYKININ TYPE PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | KDM4E 4115/4885MAPK1 3415/4885HIF1A 453/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | KDM4E 1918/4885MAPK1 1075/4885HIF1A 2558/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | KDM4E 124/4885MAPK1 1697/4885HIF1A 37/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | KDM4E 4152/4885MAPK1 1314/4885HIF1A 976/4885 |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | OXTR, CRH, TRHR | KDM4E 3872/4885MAPK1 3820/4885HIF1A 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.